Literature DB >> 9272915

Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

C B Wilson1, P W Jones, C J O'Leary, D M Hansell, P J Cole, R Wilson.   

Abstract

Bronchiectatic patients have impaired health-related quality of life (QoL) and are prone to chronic lower respiratory tract infections. We have investigated whether impaired QoL is related to sputum bacteriology. Eighty seven patients with non-cystic fibrosis (non-CF) bronchiectasis, in a stable phase of their illness, completed three QoL measures, underwent a computed tomography (CT) scan and lung function tests, and provided a fresh sputum sample for microscopy and culture. The QoL of patients colonized by Pseudomonas aeruginosa (Pa group) was significantly worse than all other patients grouped together (non-Pa group), and specifically those infected by Haemophilus influenzae (Hi group) or who had no bacterial growth (NG group) (p<0.05), but not those infected by other bacterial species (O group). The Pa group had worse lung function, but no significant differences were found between the groups for forced expiratory volume in one second (FEV1) and peak expiratory flow rate. The Pa group had significantly worse bronchiectasis scores than the O, NG and non-Pa groups, but not the Hi group. There were no significant differences between the groups with respect to the number of infective exacerbations in the last year, but the Pa group had significantly more hospital admissions. Patients infected by P. aeruginosa for more than 3 yrs had significantly worse FEV1 (p<0.03) and bronchiectasis scores (p<0.05) than those infected with P. aeruginosa for less time, but not significantly worse QoL. We conclude that, overall, patients infected with P. aeruginosa have worse quality of life, and that P. aeruginosa is associated with a greater extent of disease and worse lung function. Although patients infected with H. influenzae had extensive bronchiectasis their quality of life was better than the P. aeruginosa infected group.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272915     DOI: 10.1183/09031936.97.10081754

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  52 in total

Review 1.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 2.  Interventions for bronchiectasis: an overview of Cochrane systematic reviews.

Authors:  Emma J Welsh; David J Evans; Stephen J Fowler; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

Review 3.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 4.  Diagnosis and management of bronchiectasis.

Authors:  Maeve P Smith
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

5.  Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease.

Authors:  David E Griffith; Jennifer Adjemian; Barbara A Brown-Elliott; Julie V Philley; D Rebecca Prevots; Christopher Gaston; Kenneth N Olivier; Richard J Wallace
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

6.  Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.

Authors:  María D Maciá; David Blanquer; Bernat Togores; Jaume Sauleda; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation.

Authors:  Michael M Tunney; Gisli G Einarsson; Lan Wei; Maire Drain; Erich R Klem; Chris Cardwell; Madeleine Ennis; Richard C Boucher; Matthew C Wolfgang; J Stuart Elborn
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

Review 8.  Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.

Authors:  Katrine Fjaellegaard; Melda Dönmez Sin; Andrea Browatzki; Charlotte Suppli Ulrik
Journal:  Chron Respir Dis       Date:  2016-08-09       Impact factor: 2.444

9.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

10.  Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.

Authors:  M D Maciá; N Borrell; M Segura; C Gómez; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.